Here's a link to TZYM's Phase 2b results for their lead drug for POI: http://ir.tranzyme.com/releasedetail.cfm?ReleaseID=556399 . They are expecting pivotal Phase 3 results for this drug first half of this year. My expectations remain tempered for this lead drug due to the following: (1) limited success Entereg has had in POI; (2) TZYM's drug is an IV, not oral (like Entereg); and (3) they don't have any big name party on board (just a Euro company called Norgine that I don't know anything about).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.